Association between human immunodeficiency virus type 1 infection and cancer in the black population of Johannesburg and Soweto, South Africa.

A case-control study of 913 black cancer patients (aged 15-50 years) was undertaken to measure the association between human immunodeficiency (HIV) infection and cancers believed to have an infective aetiology. Controls were patients with cancers believed not to be infective in origin. The prevalence of HIV in the controls of 7.

A phase II study of cisplatin/ifosfamide in recurrent/metastatic undifferentiated nasopharyngeal carcinoma among young blacks in southern Africa.

Recurrent/metastatic, undifferentiated nasopharyngeal carcinoma (UDNPC) is known to be chemosensitive but has rarely been studied in Phase II methodology. No studies concerning its chemoresponsiveness among southern Africans have been demonstrated to date. From 1990 through 1994, 18 African patients from the Johannesburg metropolitan area with recurrent (following radiotherapy failure) or primarily metastatic (bone) UDNPC were treated with ifosfamide (3 g/m), mesna, and cisplatin (50 mg/m) for 2 days.

Patterns of clonal evolution in transformed chronic myelogenous leukemia.

Chronic myelogenous leukemia (CML) is an initially indolent disease which transforms into an acute leukemia about 2-5 years after diagnosis. We report a series of 75 patients, from a total of 125 patients with CML, who underwent acute blastic transformation. These included four unclassified, 10 lymphoid, and 61 non-lymphoid acute leukemias, including 54 myeloblastic, three promyelocytic, one myelomonocytic, one erythroblastic, and two megakaryoblastic leukemias.

Vincristine, Adriamycin and Dexamethasone (VAD) as Primary Therapy in Advanced Multiple Myeloma: A Single Centre Experience.

Vincristine, adriamycin and dexamethasone (VAD) combination chemotherapy was used as first line therapy in eleven patients with severe myeloma. Eight patients (73%) responded to VAD, six of them achieved complete remission (55%) with paraprotein concentrations falling to zero after a median of three treatment cycles. Median duration of response was 18.

Sequential hormonal therapy and sequential hormonal and chemotherapy for advanced prostatic cancer.

Ninety-two patients with D2 prostatic cancer were studied. Initial treatment was with either diethylstilboestrol (DES) or orchidectomy. Response to DES (5/63, 81%) was significantly higher than for orchidectomy (18/29, 62%; p less than 0.